RT Journal Article
T1 Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
A1 Castellano, Daniel
A1 Maroto, José Pablo
A1 Espinosa, Enrique
A1 Grande, Enrique
A1 Bolós, M Victoria
A1 Llinares, Julia
A1 Esteban, Emilio
A1 González Del Alba, Aranzazu
A1 Climent, Miguel Angel
A1 Arranz, Jose Angel
A1 Méndez, Mª José
A1 Fernández Parra, Eva
A1 Antón-Aparicio, Luis
A1 Bayona, Cristina
A1 Gallegos, Isabel
A1 Gallardo, Enrique
A1 Samaniego, Luz
A1 García Donas, Jesús
K1 Effectiveness
K1 routine clinical practice
K1 safety
K1 sunitinib
AB A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. To evaluate the effectiveness and safety of sunitinib in patients with advanced or mRCC in routine clinical practice. Retrospective pooled analysis of clinical data from three observational and prospective studies carried out between 2007 and 2011 in 33 Spanish hospitals. Tumor response, Progression-free survival (PFS) and overall survival (OS), and main sunitinib-related toxicities were registered. 224 patients were analyzed. Median PFS 10.6 months (95% CI: 9.02-12.25), median OS 21.9 months (95% CI: 17.2-26.6). Objective response rate (ORR) 43.8% (95% CI: 36.8-50.7). Median time to PR was 3.8 months (95% CI: 3.86-5.99) and to CR 8.2 months (95% CI: 4.75-9.77). The most common ≥ grade-3 AEs were asthenia/fatigue (18.7%), hand-foot syndrome (6.2%), hypertension (5.8%) and neutropenia (4.8%). Hand-foot syndrome, diarrhea and mucositis were confirmed as independent predictors for PFS and/or OS in a multivariate analysis (p 
YR 2017
FD 2017-08-28
LK http://hdl.handle.net/10668/11225
UL http://hdl.handle.net/10668/11225
LA en
DS RISalud
RD Apr 10, 2025